Alopecia Areata
Conditions
Interventions
Control group:The drug was administered intralesionally using a standard syringe. The treatment regimen consisted of 1 ml of compound betamethasone injection (1 ml/vial, containing 5 mg of betamethaso
Experimental group:The drug was administered using a hollow microneedle (PA-NDL9P34G1 9PIn Screw Multi Needle, manufactured by Derma Shine, South Korea). The microneedle length was set to 2.0 mm. Apar
Sponsors
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
20 Years to 53 Years
Inclusion criteria
Inclusion criteria: A. Age between 18 and 55 years. B. Diagnosis of alopecia areata (AA) based on clinical presentation and trichoscopy. C. Disease type classified as patchy alopecia areata. D. Disease severity classified as mild to moderate (Severity of Alopecia Tool score, i.e., SALT < 50). E. Negative hair pull test. F. Disease duration = 6 months.
Exclusion criteria
Exclusion criteria: A. Severe AA with a SALT score = 50, including alopecia totalis. B. Involvement of hair beyond the scalp, including eyebrows, eyelashes, beard, axillary hair, pubic hair, or other body hair, including alopecia universalis. C. Presence of other conditions that could cause alopecia-like hair loss, such as androgenetic alopecia, syphilitic alopecia, trichotillomania, telogen effluvium, hair loss secondary to thyroid or other endocrine diseases, or scarring alopecia. D. Receipt of other localized treatments for AA within 4 weeks prior to enrollment, such as plum-blossom needle, roller needle, phototherapy, laser treatment, cryotherapy, hair transplantation, topical hair growth promoters (e.g., minoxidil solution, platelet-rich plasma, bimatoprost), topical irritants (e.g., anthralin, tazarotene, capsaicin tincture), topical immunotherapy (e.g., DPCP, SADBE), topical corticosteroids, topical tacrolimus ointment, or intralesional injections of corticosteroids or immunosuppressants. E. Receipt of systemic treatments for AA within 12 weeks prior to enrollment, including oral or injectable medications such as statins, antihistamines, corticosteroids, JAK inhibitors, PDE4 inhibitors, biologics (e.g., abatacept, IFN-? monoclonal antibody), immunosuppressants (e.g., methotrexate, cyclosporine), or traditional Chinese medicine. F. Presence of other conditions that may affect efficacy or safety evaluations, such as other active inflammatory skin diseases, other scalp-involving diseases, or scalp trauma. G. Presence of serious uncontrolled hypertension, diabetes, cardiovascular diseases, cerebrovascular diseases, or other severe underlying conditions. H. Presence of other contraindications to corticosteroid use or history of allergies to corticosteroids. I. Pregnancy, breastfeeding, or planning to become pregnant in the near future. J. Any other conditions deemed unsuitable for study participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of Alopecia Tools (SALT) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trichoscopy results;Scalp Photography;Pain visual analog scale score;Adverse reactions and safety indicators; | — |
Countries
China
Contacts
Public ContactJiang Yiqun
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed